Hormonal therapy of gynecologic cancers.
Progestins produce objective responses in about 30% of unselected patients with metastatic adenocarcinoma of the uterus. Selection of patients for treatment based on the presence of progesterone receptors may increase the probability of a response. There is little evidence to support a role of hormones as adjuvants in the primary management of poor-risk patients or in combination with chemotherapy. Antiestrogens may have a role as secondary agents in adenocarcinoma of the uterus, and progestins may have a role as secondary agents in ovarian cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000236:Adenoma / Q000188:drug therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008535:Megestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019290:Megestrol Acetate; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D014594:Uterine Neoplasms / Q000188:drug therapy*
D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D008535:Megestrol; D019290:Megestrol Acetate